doi: 10.3121/cmr.2010.908 trial fibrillation (AF) and heart failure are very closely linked. 1 Atrial fibrillation is the most common sustained arrhythmia in patients with heart failure. 2 Patients with heart failure have a five to ten-fold greater probability of developing this arrhythmia than those without heart failure. [3] [4] [5] A To what extent the presence and development of this arrhythmia retains a prognostic role in patients with heart failure remains debatable. [6] [7] [8] [9] [10] [11] [12] [13] To date, few studies have evaluated the predictive value of new onset AF in heart failure populations, with contradictory results. 7, [9] [10] [11] [14] [15] [16] [17] Analyses specifically exploring the role of AF in the subset of patients affected by idiopathic dilated cardiomyopathy (IDCM) are even more scarce and report highly conflicting data. [18] [19] [20] Most of these studies lack information about the natural history of AF in patients who are optimally managed with angiotensin-converting enzyme (ACE) inhibitor and beta-blocker therapy. Thus, we sought to examine the prevalence, incidence, risk factors for AF development, and long-term prognostic implications of this arrhythmia in a large, single center, well-characterized population of young patients with IDCM on optimal therapy.
Methods

Subjects
Data were obtained from the Heart Muscle Disease Registry of Trieste, Italy, a single-center database. This Registry was developed by the Department of Cardiology in Trieste, an established Italian referral center for screening, diagnosis, and treatment of IDCM. All patients signed informed consent prior to enlistment in the Registry. This study conformed to [23] [24] [25] and on the empiric data of our clinical experience with patients with IDCM.
Definitions and end-points
Atrial fibrillation was diagnosed using standard electrocardiographic criteria: irregular The onset of heart failure was defined by the onset of heart failure symptoms. Patients who were asymptomatic at the first evaluation in our clinic, without a history of heart failure symptoms and with LV systolic dysfunction at echocardiogram, were considered as patients doi: 10.3121/cmr.2010.908
affected by IDCM in NYHA class I. We considered patients with a previous episode of acute heart failure or receiving diuretics at index evaluation in our center as patients with a history of heart failure. Body mass index (BMI) was estimated using the standard formula (body weight in kilograms divided by squared height in meters).
We analyzed the impact of AF present at baseline or developed during follow-up on all cause mortality/urgent heart transplantation. For the purpose of our study, urgent heart transplantation was considered in status I, indicated in patients with refractory heart failure needing inotropic treatment and/or mechanical support of the circulation. Table 1 summarizes the baseline characteristics of patients of the entire study cohort. At enrollment 52 patients (9.6%) in our study population had AF (1 patient had persistent AF; the remaining 51 had permanent AF). Patients with AF were more likely to be males, slightly older, had more dilated left atrium and less dilated left ventricle. Among patients with or without AF there were no differences in terms of comorbidities, treatment with ACE , 8% ), or because they had a single episode of AF (7 patients, 54%).
Statistical analysis
Results
Patient population
Development of AF during the study
Twenty-eight (5.7%) of 487 patients in sinus rhythm at baseline developed new AF in the course of the study. The rate of occurrence of AF was 0.8 % per year and was evenly distributed during follow-up. Ten patients (36%) with new onset AF, after one or more attempts to convert to sinus rhythm, remained in permanent AF. At baseline, patients who would later develop AF were in a more advanced NYHA class and had more severe LV systolic and diastolic dysfunction (Table 2) At multivariate logistic regression analysis, the independent predictors for new AF were a more dilated left atrium (for every 2cm 
Survival analysis
During a mean follow-up of 90 ± 58 months, 156 (28.9 %) out of 539 patients with IDCM died or underwent urgent heart transplantation in status I; 137 (28 %) of 487 patients in sinus rhythm, and 19 (36.5 %) of 52 patients with AF (P = 0.28) (figure 1). At Cox proportional hazards model including all 539 patients, baseline AF was not independently associated to death/urgent heart transplantation ( Table 3 ).
The impact of new onset AF was analyzed in 487 patients without previous documentation or symptoms of AF and in sinus rhythm at enlistment in the Registry. Of 28 patients with new onset AF, 16 patients (57.1%) died or underwent urgent heart transplantation in comparison to 121 patients (26.4%) of 459 patients who maintained sinus rhythm during follow-up (P < 0.001). The landmark analysis showed that patients developing AF in the first three years after diagnosis had a significantly higher risk of death or urgent heart transplantation ( figure   2 ). Moreover, at multivariate analysis, new onset AF (treated as a time dependent variable and adjusted for the other significant time-dependent parameters) was an independent predictor of subsequent all-cause mortality/heart transplantation (HR 3.67, 95% CI 2.07-6.5, P < 0.001) ( Table 4) .
Discussion
Idiopathic dilated cardiomyopathy is a rare heart muscle disease (incidence 5 to 8 cases per 100,000 population per year 27 ) characterized by left ventricular or biventricular dilatation and impaired myocardial contractility. Since previous studies that explored the impact of AF in the setting of IDCM are outdated and contradictory, [18] [19] [20] we evaluated the impact of AF on outcome in a large, single center, well-characterized population of patients with IDCM on long-term, optimal medical treatment with ACE inhibitors and beta blockers.
The prevalence of AF was found to depend on the severity of heart failure. The prevalence of AF at baseline in our patients was relatively low (9.6%). Similarly, in a large study by Dries et al, 7 including patients with mild to moderate heart failure, the prevalence of AF was 6%. In clinical trials enrolling patients with more advanced heart failure, AF at baseline ranges between 19% and 50%. 6, 8, 12, 33 Patients from our study with either AF or sinus rhythm at enrollment did not differ in duration and severity of heart failure. We did not observe a difference in survival between patients with AF and sinus rhythm at baseline.
There is no consensus regarding the prognostic role of baseline AF in heart failure patients.
Two trials have analyzed the prognostic impact of AF in heart failure patients on optimal medical treatment with ACE inhibitors and beta blockers to date. The first one is a subanalysis of the COMET trial 9 that included 3,029 patients treated with beta blockers during a follow-up of 58 months. The authors found that the presence of AF at baseline was associated The difference in our results may be due to the diversity of the study population and the etiology of heart failure. Since in our population no difference existed regarding the duration and severity of the heart failure among patients with AF or sinus rhythm, one may speculate that AF present at baseline is not a marker of important hemodynamic impairment, but possibly the expression of a specific genetic mutation that causes early susceptibility to arrhythmias in some patients with IDCM. Consequently, there is no association between AF at enrollment and outcome. Furthermore, the patients enrolled in pharmacologic trials do not fully represent patients from clinical practice due to exclusion criteria such as relevant comorbidities or prevalent diastolic dysfunction.
Clinical implications of new onset AF
During a mean follow-up of over seven years, 5.7% of patients in sinus rhythm at baseline and without previous history of AF developed this arrhythmia. Patients with new onset AF were more frequently in advanced NYHA class. The development of AF was associated with a more important left atrial dilatation, and with a more severe LV systolic dysfunction. The sustained atrial overload present in heart failure causing atrial enlargement may facilitate the occurrence and persistence of AF. 34 Other mechanisms contributing to AF development are the elevated concentrations of catecholamine and angiotensin II that may promote atrial fibrosis, 35, 36 and thus induce changes in atrial conduction. Neurohumoral modulation and doi: 10.3121/cmr.2010.908
blockade of adrenergic receptors with ACE inhibitors and beta blockers could explain the efficacy of these drugs in preventing AF in patients with heart failure. 37, 38 Among our patients the incidence and prevalence of AF was relatively low, and this may be due to the extensive use of ACE inhibitors and beta blockers.
In our study, new onset AF considered as a time dependent covariate, and adjusted for other important covariates, was found to be an independent predictor of poor outcome.
Only a few other studies have evaluated the incidence and predictive role of new onset AF.
The incidence of new onset AF in the study by Pozzoli et al, 14 including patients with heart failure referred for evaluation for heart transplantation, was 9% during a mean follow-up of 19 months. Similarly, in our study new onset AF was associated with major cardiac events only in the first 10 months from the onset, but had no influence on patients who lived longer than that period. In the COMET study, 9 the incidence of new onset AF was higher (23%) than in our study. The higher incidence might be due to the inclusion of older patients with a lower LVEF. In addition, patients with a history of AF but in sinus rhythm at baseline ECG, were included in the non-AF group. However, new onset AF was an independent predictor of subsequent all-cause mortality in the COMET trial. 9 The development of AF during follow-up might represent a late, secondary event in patients with long-lasting and more advanced chronic heart failure. On the other hand, its development may itself contribute to the progression of the disease and to a poor outcome.
However, patients with IDCM who develop AF late during follow-up represent a subgroup of patients with more advanced disease who need a closer follow-up and further optimization of standard therapy.
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The difference we observed in the impact of baseline AF and new onset AF on outcome may be due to the different underlying pathophysiological mechanism of the arrhythmia. The first may represent an early manifestation of IDCM in the context of specific genetic variants.
New onset AF characterizes a late stadium of the disease with a more important hemodynamic impairment; however, further studies are necessary to elucidate this issue.
Study limitations
There are some limitations in our study that must be acknowledged.
1)
We cannot rule out undocumented, asymptomatic, short, self-limited episodes of AF in patients who were in sinus rhythm at follow-up visits. 2) Our study is a retrospective study and may be subject to the potential biases of such studies. However, it included a large population of patients with IDCM enrolled in a single-center Registry, with prospective and strict inclusion criteria, and a long-term follow-up. Usually, in Registries there is a particular concern about the change of treatment through different historical periods. In our Registry all patients without contraindications were on treatment with ACE inhibitors and beta blockers.
3) Atrial fibrillation is usually associated with a more advanced stage of heart failure, and its development and specific role on long-term prognosis may be difficult to analyze. In our study the development of AF through the study period was independently associated with a worse outcome using a time-dependent model and after adjustment for all other clinical and instrumental prognostic variables. In spite of these limitations, we believe that our analysis provides an important and reliable addition to the literature in this field.
Conclusions
The prevalence of AF in our long cohort of optimally treated patients with IDCM was close to 10%. The incidence of new onset AF throughout the long-term follow-up was nearly 1/100 patients/year. New onset AF was independently predicted by a more severe left ventricular dysfunction and a more dilated left atrium. The early development of AF during follow-up but not baseline AF was an independent marker of worse outcome in IDCM. 
